ARTICLE | Clinical News
CY-503: Phase II started
September 21, 2009 7:00 AM UTC
Cytavis began a double-blind, placebo-controlled, Austrian and German Phase II trial to compare 350 ng subcutaneous Aviscumine given twice weekly in about 250 chemotherapy-refractory patients. ...